Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Vancomycin-resistant S. aureus was cultured from the exit site of a temporary dialysis catheter of a patient with diabetes, peripheral vascular disease, and persistent foot ulcers. The organism carried the vanA resistance gene, which may have come from the vancomycin-resistant Enterococcus faecalis that was also isolated from the patient, who had received vancomycin for several weeks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increasing rates of oxacillin-resistant S aureus or MRSA isolates in both hospital and community settings and the recovery of clinical S aureus isolates both partially and fully 138,139 resistant to vancomycin have complicated the treatment of S aureus IE.”
In the citing paper
“the recovery of clinical S aureus isolates both partially and fully 138,139 resistant to vancomycin have complicated the treatment of S aureus IE.”
In the citing paper
“and is especially prevalent in North America.6,138,139”
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Medical Entomology and Zoology · Cited by 17,248
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Diagnostic molecular microbiology : principles and applications
Persing, D. H. (1993) · ASM Press eBooks · Cited by 1,311
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Self-citation(2001) · PsycEXTRA Dataset · doi:10.1037/e548252006-001 · Cited by 1,018
Noble, W. C., Virani, Z., & Cree, R. G. A. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05089.x · Cited by 627
Arthur, M., Molinas, C., Depardieu, F., & Courvalin, P. (1993) · Journal of Bacteriology · doi:10.1128/jb.175.1.117-127.1993 · Cited by 603
Pulsed-field gel electrophoresis as a replacement for bacteriophage typing of Staphylococcus aureus
Bannerman, T. L., Hancock, G. A., Tenover, F. C., & Miller, J. M. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.3.551-555.1995 · Cited by 550
Self-citationCharacterization of glycopeptide-resistant enterococci from U.S. hospitals
Clark, N. C., Cooksey, R. C., Hill, B. C., Swenson, J. M., & Tenover, F. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2311 · Cited by 395
Self-citationApplication of pulsed-field gel electrophoresis to molecular epidemiology
Maslow, J. N. (1993) · Medical Entomology and Zoology · Cited by 382
Research works printed but not linked: 7
- 1997, MMWR Morb Mortal Wkly Rep, 46, 624
- 2000, MMWR Morb Mortal Wkly Rep, 48, 1165
- 2002, MMWR Morb Mortal Wkly Rep, 51, 565
- Kloos WE, Bannerman TL. Staphylococcus and Micrococcus. In: Murray PR, ed. Manual of clinical microbiology. 7th ed. Washington, D.C.: ASM Press, 1999:264-82.
- 2001, MMWR Morb Mortal Wkly Rep, 50, 1
- 1995, MMWR Morb Mortal Wkly Rep, 44, 1
- 1997, MMWR Morb Mortal Wkly Rep, 46, 626
Cited by
Items 301–400 of 1,000
Correlation between serum linezolid concentration and the development of thrombocytopenia
Hiraki, Y., Tsuji, Y., Hiraike, M., Misumi, N., Matsumoto, K., Morita, K., Kamimura, H., & Karube, Y. (2011) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548.2011.608712 · Cited by 61
Turner, A. M., Lee, J. Y. H., Gorrie, C. L., Howden, B. P., & Carter, G. P. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.637656 · Cited by 68
Treatment of Resistant Enterococcal Urinary Tract Infections
Swaminathan, S., & Alangaden, G. J. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0138-8 · Cited by 68
Daptomycin: A cyclic lipopeptide antimicrobial agent
Jeu, L., & Fung, H. B. (2004) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.11.014 · Cited by 61
α and β Chains of Hemoglobin Inhibit Production of Staphylococcus aureus Exotoxins
Schlievert, P. M., Case, L. C., Nemeth, K. A., Davis, C. C., Sun, Y., Qin, W., Wang, F., Brosnahan, A. J., Mleziva, J. A., Peterson, M. L., et al. (2007) · Biochemistry · doi:10.1021/bi701202w · Cited by 59
Evolution of Staphylococcus aureus during human colonization and infection
Fitzgerald, J. R. (2013) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2013.04.020 · Cited by 68
Scherl, A., François, P., Bento, M., Deshusses, J., Charbonnier, Y., Converset, V., Huyghe, A., Walter, N., Hoogland, C., Appel, R. D., et al. (2004) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2004.09.017 · Cited by 67
Cheng, J., Chin, W., Dong, H., Xu, L., Zhong, G., Huang, Y., Li, L., Xu, K., Wu, M., Hedrick, J. L., et al. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500471 · Cited by 58
Molecular basis of antibiotic multiresistance transfer in Staphylococcus aureus
Edwards, J. S., Betts, L., Frazier, M. L., Pollet, R. M., Kwong, S. M., Walton, W. G., Ballentine, W. K., Huang, J. J., Habibi, S., Campo, M. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219701110 · Cited by 66
Amycolamicin: A Novel Broad‐Spectrum Antibiotic Inhibiting Bacterial Topoisomerase
Sawa, R., Takahashi, Y., Hashizume, H., Sasaki, K., Ishizaki, Y., Umekita, M., Hatano, M., Abe, H., Watanabe, T., Kinoshita, N., et al. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201202645 · Cited by 58
Anti–Methicillin-Resistant Staphylococcus aureus Nanoantibiotics
Labruère, R., Sona, A. J., & Turos, E. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01121 · Cited by 53
The application of machine learning techniques to innovative antibacterial discovery and development
Serafim, M. S. M., Kronenberger, T., Oliveira, P. R., Poso, A., Honório, K. M., Mota, B. E. F., & Maltarollo, V. G. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1776696 · Cited by 63
González‐Zorn, B., Senna, J. P. M., Fiette, L., Shorte, S. L., Testard, A., Chignard, M., Courvalin, P. M., & Grillot‐Courvalin, C. (2005) · Infection and Immunity · doi:10.1128/iai.73.3.1847-1851.2005 · Cited by 71
“Due to multiresistance of these strains, including recent acquisition of high-level glycopeptide resistance (3), few antibiotics remain effective for MRSA infections.”
BackgroundAntibiotic resistance in Staphylococcus aureus and its relevance in therapy
Bal, A. M., & Gould, I. M. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.13.2257 · Cited by 61
“[26] isolated a strain of MRSA that was highly resistant to vancomycin with an MIC of 1024 μg/ml from a patient in Michigan.”
BackgroundLü, W., Oberthür, M., Leimkuhler, C., Tao, J., Kahne, D. E., & Walsh, C. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400277101 · Cited by 58
Harro, C., Betts, R., Orenstein, W., Kwak, E.-J., Greenberg, H. E., Onorato, M. T., Hartzel, J., Lipka, J., DiNubile, M. J., & Kartsonis, N. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00356-10 · Cited by 57
“Geometric mean antibody concn ( g/ml) 55 (35, 88) 119 (84, 168) 156 (110, 223) 15 (9, 27) Geometric mean fold rise in antibody concn from baseline 2.”
BackgroundPotency and Bactericidal Activity of Iclaprim against Recent Clinical Gram-Positive Isolates
Sader, H. S., Fritsche, T. R., & Jones, R. N. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00129-09 · Cited by 57
“, no criteria have been established by the CLSI (1).”
BackgroundInfluentialAntibacterial Efficacy Testing of a Bioelectric Wound Dressing Against Clinical Wound Pathogens
Kim, H., Makin, I. R. S., Skiba, J. B., Ho, A., Housler, G., Stojadinovic, A., & Izadjoo, M. J. (2014) · The Open Microbiology Journal · doi:10.2174/1874285801408010015 · Cited by 61
Akpaka, P. E., Roberts, R., & Monecke, S. (2016) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2016.05.010 · Cited by 60
Tang, H.-J., Chen, C.-C., Ko, W., Yu, W., Chiang, S., & Chuang, Y.-C. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.02.013 · Cited by 60
Rebiahi, S., Abdelouahid, D. E., Rahmoun, M. N., Abdelali, S., & Azzaoui, H. (2011) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2011.09.010 · Cited by 55
“Weigel et al. (2003) demonstrated that a genetic transfer from an Enterococcus feacalis strain to a MRSA allowed the passage of Tn 1546 carrying genetic determinants such as van A [39].”
BackgroundSynthesis and biological activity of N-Acylated ornithine analogues of daptomycin
Hill, J., Siedlecki, J. M., Parr, I. B., Morytko, M. J., Yu, X., Zhang, Y., Silverman, J. A., Controneo, N., Laganas, V. A., Li, T., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.07.019 · Cited by 55
Pletz, M. W., Burkhardt, O., & Welte, T. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-12-507 · Cited by 55
Indrawattana, N., Sungkhachat, O., Sookrung, N., Chongsa-nguan, M., Tungtrongchitr, A., Voravuthikunchai, S. P., Kong-Ngoen, T., Kurazono, H., & Chaicumpa, W. (2013) · BioMed Research International · doi:10.1155/2013/314654 · Cited by 55
Lundstrom, T. S., & Sobel, J. D. (2004) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2004.04.014 · Cited by 60
“In 2002, the first naturally occurring vancomycin-resistant S aureus (VRSA) infection was described in a patient receiving long-term hemodialysis in Michigan at an outpatient dialysis center [45].”
BackgroundMethodInfluentialMenges, R., Muth, G., Wohlleben, W., & Stegmann, E. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-1139-x · Cited by 55
“Recently, first vancomycin-resistant S. aureus isolates from patients with clinical infections have been described (Chang et al. 2003).”
BackgroundGoldberg, E., Paul, M., Talker, O., Samra, Z., Raskin, M., Hazzan, R., Leibovici, L., & Bishara, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq179 · Cited by 55
Xin, B., Zheng, J., Liu, H., Li, J., Ruan, L., Peng, D., Sajid, M., & Sun, M. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01115 · Cited by 57
“However, the emergence of vancomycin-resistant enterococci (VRE) and vancomycin-resistant staphylococci attenuated its application in recent years (Leclercq et al., 1988; Uttley et al., 1988; Centers for Disease Control and Prevention, 1997; Chang et al., 2003; Courvalin, 2006).”
BackgroundMolechan, C., Amoako, D. G., Abia, A. L. K., Somboro, A. M., Bester, L. A., & Essack, S. Y. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.07.324 · Cited by 60
Fox, P. M., Lampen, R. J., Stumpf, K. S., Archer, G. L., & Climo, M. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00232-06 · Cited by 58
“While VRS1 is reported to be susceptible to a number of other antibiotics available for treatment, most of the MICs reported for these agents are only one dilution below the susceptibility breakpoint (7).”
BackgroundHarigaya, Y., Bulitta, J. B., Forrest, A., Sakoulas, G., Lesse, A. J., Mylotte, J. M., & Tsuji, B. T. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01585-08 · Cited by 55
Jones, M. E., Draghi, D. C., Karlowsky, J. A., Sahm, D. F., & Bradley, J. S. (2004) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-3-3 · Cited by 57
Antibiotic Resistance and the MRSA Problem
Vestergaard, M. R., Frees, D., & Ingmer, H. (2019) · ASM Press eBooks · doi:10.1128/9781683670131.ch47 · Cited by 58
Mehmood, N., Akram, M. W., Majeed, M. I., Nawaz, H., Aslam, M. A., Naman, A., Wasim, M., Ghaffar, U., Kamran, A., Nadeem, S., et al. (2024) · RSC Advances · doi:10.1039/d3ra07575c · Cited by 53
Staphylococcus aureus: the search for novel targets
García-Lara, J., Masalha, M., & Foster, S. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03432-x · Cited by 69
Active Export Proteins Mediating Drug Resistance in Staphylococci
Hassan, K. A., Skurray, R. A., & Brown, M. H. (2007) · Microbial Physiology · doi:10.1159/000099640 · Cited by 53
“…was the development of high-level vancomycin resistance in S. aureus via the acquisition of the vanA vancomycin resistance determinant from enterococci and the incorporation of this determinant onto a pSK41-like conjugative plasmid [Chang et al., 2003; Firth and Skurray, 2006; Weigel et al., 2003].”
BackgroundSabia, C., Niederhäusern, S. D., Guerrieri, E., Messi, P., Anacarso, I., Manicardi, G. C., & Bondi, M. (2007) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2007.03612.x · Cited by 61
“…responsible for the transferability of vanA genes, is generally harboured in a plasmid with a similar molecular weight (Leclercq et al. 1988; Chang et al. 2003). ª 2007 The Authors Journal compilation ª 2007 The Society for Applied Microbiology, Journal of Applied Microbiology 104 (2008)…”
BackgroundBourgeois-Nicolaos, N., Moubareck, C., Mangeney, N., Butel, M.-J., & Doucet-Populaire, F. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2005.00004.x · Cited by 50
Derivatives of a Vancomycin-ResistantStaphylococcus aureusStrain Isolated at Hershey Medical Center
Bozdoğan, B., Ednie, L. M., Credito, K. L., Kosowska, K., & Appelbaum, P. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4762-4765.2004 · Cited by 58
“aureus (VRSA) strains were isolated from foot ulcers of patients with circulation disorders in the lower limbs concomitant with amputation histories (5, 19).”
BackgroundBrinsley-Rainisch, K. J., Sinkowitz‐Cochran, R. L., Cardo, D. M., & The CDC Campaign to Prevent Antimicrobial Resistance Team (2005) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.12.004 · Cited by 59
Self-citationVaudaux, P. E., Huggler, E., Bernard, L., Ferry, T., Renzoni, A., & Lew, D. P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00269-10 · Cited by 53
“5 14 (25) 0 (0) 0 (0) 0 (0) 0 (0) 13 (23) 1 (2) 0 (0) 0 (0) 0 (0) 1 30 (54) 3 (5) 1 (2) 1 (2) 1 (2) 26 (46) 5 (9) 5 (9) 4 (7) 3 (5) 2 5 (9) 45 (80) 40 (71) 36 (64) 35 (62) 4 (7) 26 (46) 8 (14) 8 (14) 8 (14) 4 3 (5) 6 (11) 13 (23) 17 (30) 18 (32) 3 (5) 22 (39) 36 (64) 28 (50) 23 (41) 8 0 (0) 2 (4) 2 (4) 2 (4) 2 (4) 0 (…”
BackgroundWong, T., Liao, S.-Z., Ko, W., Wu, C., Wu, S. B., Chuang, Y.-C., & Huang, I. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030411 · Cited by 53
“However, vancomycin resistance has also become a new challenge in recent years [10,11].”
BackgroundGlobal Priority Pathogens: Virulence, Antimicrobial Resistance and Prospective Treatment Options
Campos, J. C. D. M., Antunes, L. C. M., & Ferreira, R. B. R. (2020) · Future Microbiology · doi:10.2217/fmb-2019-0333 · Cited by 56
Antimicrobial resistance among gram-positive organisms in the intensive care unit
Clark, N. M., Hershberger, E., Zervosc, M. J., & Lynch, J. P. (2003) · Current Opinion in Critical Care · doi:10.1097/00075198-200310000-00011 · Cited by 63
Severin, A. I., Wu, S. W., Tabei, K., & Tomasz, A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4566-4573.2004 · Cited by 51
“aureus has created, for the first time in clinical history, highly VRSA strains (6).”
BackgroundAbdelraheem, W. M., Khairy, R. M. M., Zaki, A. I., & Zaki, S. (2021) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-021-00459-2 · Cited by 55
Analysis of the Bacterial Heat Shock Response to Photodynamic Therapy‐mediated Oxidative Stress
Denis, T. G. S., Huang, L., Dai, T., & Hamblin, M. R. (2011) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2011.00902.x · Cited by 50
Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria
Eliopoulos, G. M. (2009) · Journal of Infection · doi:10.1016/s0163-4453(09)60004-9 · Cited by 52
Hirschwerk, D., Ginocchio, C. C., Bythrow, M., & Condon, S. (2006) · Infection Control & Hospital Epidemiology · doi:10.1086/502688 · Cited by 49
New treatments for methicillin-resistant Staphylococcus aureus
Stryjewski, M. E., & Corey, G. R. (2009) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32832f0a74 · Cited by 59
Sorlózano, A., Fernández, J. G., Martinez, T., Yuste, M. E., Pérez-López, J. A., Vindel, A., Guillen, J., & Boquete, T. (2009) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0823-4 · Cited by 51
“aureus, GRSA) [5].”
Phytochemical Analysis and Biological Activities ofCola nitidaBark
Dah-Nouvlessounon, D., Adoukonou‐Sagbadja, H., Nafan, D., Sina, H., Adjanohoun, A., Inoussa, M., Akakpo, D., Gbénou, J., Kotchoni, S. O., Dicko, M. H., et al. (2015) · Biochemistry Research International · doi:10.1155/2015/493879 · Cited by 52
Cruz, C., Moreno, J., Renzoni, A., Hidalgo, M., Reyes, J., Schrenzel, J., Lew, D., Castañeda, E., & Arias, C. A. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2005.08.013 · Cited by 49
Hassan, D., Omolo, C. A., Gannimani, R., Waddad, A. Y., Mocktar, C., Rambharose, S., Agrawal, N., & Govender, T. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.01.010 · Cited by 52
Nano-enabled strategies to combat methicillin-resistant Staphylococcus aureus
Singh, S., Numan, A., Somaily, H. H., Gorain, B., Ranjan, S. K., Rilla, K. J., Siddique, H. R., & Kesharwani, P. (2021) · Materials Science and Engineering C · doi:10.1016/j.msec.2021.112384 · Cited by 55
Nailor, M. D., & Sobel, J. D. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.010 · Cited by 54
Antibody responses in patients with invasive Staphylococcus aureus infections
Jacobsson, G., Colque‐Navarro, P., Gustafsson, E., Andersson, R., & Möllby, R. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-010-0919-x · Cited by 49
Gales, A. C., Sader, H. S., & Jones, R. N. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.01051.x · Cited by 49
“aureus have also been detected following acquisition of the vanA operon [6,7].”
BackgroundInfluentialIn Vitro Activity of the New Quinolone WCK 771 against Staphylococci
Jacobs, M. R., Bajaksouzian, S., Windau, A., Appelbaum, P. C., Patel, M. V., Gupte, S. V., Bhagwat, S., de Souza, N. J., & Khorakiwala, H. F. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3338-3342.2004 · Cited by 50
“In recent bloodstream isolates in the United States, susceptibility of me- thicillin-susceptible staphylococci to ciprofloxacin was high (94.3% for S. aureus and 89.9% for coagulase-negative staphylococci); however, 88.6% of methicillin-resistant S. aureus isolates were resistant to ciprofloxacin, as were 54.9% of coa…”
BackgroundInfluentialVancomycin: Understanding Its Past and Preserving Its Future
Levine, D. P. (2008) · Southern Medical Journal · doi:10.1097/smj.0b013e3181647037 · Cited by 49
“Unresolved Issues Reports of VRE, VISA, hVISA, and VRSA raise doubts about vancomycin’s future efficacy.(17,18,25,38) Although the incidence of strains with reduced susceptibility to vancomycin seems low, the true incidence may be much higher because of technical difficulties with common methods of detection.”
BackgroundHo, C.-M., Hsueh, P., Liu, C., Lee, S.-Y., Chiueh, T.-S., Shyr, J.-M., Tsao, S.-M., Chuang, Y.-C., Yan, J.-J., Wang, L.-S., et al. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-009-0868-4 · Cited by 51
“The resistance mechanism for VRSA involves transfer of the vanA gene resistance determinants from vancomycinresistant enterococcus (VRE) [8].”
BackgroundRocchetti, T. T., Martins, K. B., Faccioli-Martins, P. Y., de Oliveira, R. A., Mondelli, A. L., Fortaleza, C. M. C. B., & da Cunha, M. D. L. R. D. S. (2018) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2018.02.006 · Cited by 48
Jelínková, P., Šplíchal, Z., Jimenez, A. M. J., Haddad, Y., Mazumdar, A., Sur, V. P., Milosavljević, V., Kopel, P., Buchtelová, H., Guráň, R., et al. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s160975 · Cited by 50
Therapeutic compounds targeting Lipid II for antibacterial purposes
Malin, J. J., & de Leeuw, E. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s215070 · Cited by 50
“This type of resistance is transferable to significant pathogens like MRSA due to its location on conjugative plasmids.(58,59) The dissemination of glycopeptide resistance in enterococci can therefore lead to clinical isolates that are resistant to all available antibiotics.”
BackgroundDevelopment and Research Progress of Anti-Drug Resistant Bacteria Drugs
Cui, X., Lü, Y., & Yue, C. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s338987 · Cited by 50
“can lead to bacteremia (blood infection) and even death.(31) As Gram-negative bacteria (GNB), Escherichia”
BackgroundMatsumura, Y., Yamamoto, M., Gomi, R., Tsuchido, Y., Shinohara, K., Noguchi, T., & Nagao, M. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-22 · Cited by 57
Adegoke, A. A., & Okoh, A. I. (2013) · Folia Microbiologica · doi:10.1007/s12223-013-0275-1 · Cited by 47
Management of Infected Grafts and Aneurysms of the Aorta
Kitamura, T., Morota, T., Motomura, N., Ōno, M., Shibata, K., Ueno, K., Kotsuka, Y., & Takamoto, S. (2005) · Annals of Vascular Surgery · doi:10.1007/s10016-005-0006-4 · Cited by 47
ANTI‐INFECTIVE THERAPY AT END OF LIFE: ETHICAL DECISION‐MAKING IN HOSPICE‐ELIGIBLE PATIENTS
Ford, P. J., Fraser, T. G., Davis, M. P., & Kodish, E. D. (2005) · Bioethics · doi:10.1111/j.1467-8519.2005.00450.x · Cited by 47
Jones, R. N., Fritsche, T. R., Sader, H. S., & Goldstein, B. P. (2005) · Journal of Chemotherapy · doi:10.1179/joc.2005.17.6.593 · Cited by 47
Can virulence factors be viable antibacterial targets?
Marra, A. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.1.61 · Cited by 51
Novel Mechanism of Resistance to Glycopeptide Antibiotics in Enterococcus faecium
Cremniter, J., Mainardi, J., Josseaume, N., Quincampoix, J.-C., Dubost, L., Hugonnet, J., Marie, A., Gutmann, L., Rice, L. B., & Arthur, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606920200 · Cited by 46
Carbon dots for highly effective photodynamic inactivation of multidrug-resistant bacteria
Rabe, D., Mohammed, O. O., Dong, X., Patel, A. K., Overton, C. M., Tang, Y., Kathariou, S., Sun, Y., & Yang, L. (2020) · Materials Advances · doi:10.1039/d0ma00078g · Cited by 46
Khan, Z. A., Goda, E. S., Rehman, A. U., & Sohail, M. (2021) · Materials Science and Engineering B · doi:10.1016/j.mseb.2021.115146 · Cited by 46
Microbiology of nosocomial infections: progress and challenges
Struelens, M. J., Denis, O., & Rodriguez‐Villalobos, H. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.05.015 · Cited by 58
Confronting bacterial resistance in healthcare settings: a crucial role for microbiologists
McGowan, J. E., & Tenover, F. C. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro845 · Cited by 55
Self-citationDaptomycin: first in a new class of antibiotics for complicated skin and soft-tissue infections
Kern, W. V. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00885.x · Cited by 48
Cruz, K. C. P., Enekegho, L. O., & Stuart, D. T. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.890479 · Cited by 50
“Bacterial strains with resistance to virtually all currently employed antibiotic drugs have been identified (Chang et al., 2003).”
BackgroundSharma, S., Barman, P., Joshi, S., Preet, S., & Saini, A. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.112303 · Cited by 52
Pharmacokinetics and pharmacodynamics of peptide antibiotics
Bian, X., Qu, X., Zhang, J., Nang, S. C., Bergen, P. J., Zhou, Q. T., Chan, H., Feng, M., & Li, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114171 · Cited by 47
New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides
Tran, T. T., Villegas, S. G., Aitken, S. L., Butler‐Wu, S. M., Soriano, À., Werth, B. J., & Munita, J. M. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02614-20 · Cited by 46
Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models
Patel, M. V., de Souza, N. J., Gupte, S. V., Jafri, M., Bhagwat, S., Chugh, Y., Khorakiwala, H. F., Jacobs, M. R., & Appelbaum, P. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4754-4761.2004 · Cited by 45
“aureus (VRSA) strains (3, 5, 8), which compromise the therapeutic value of vancomycin.”
BackgroundMiró, J. M., García-de-la-Mària, C., Armero, Y., de Lazzari, E., Soy, D., Moreno, A., del Río, A., Almela, M., Mestres, C. A., Gatell, J. M., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01266-06 · Cited by 46
Vancomycin resistant enterococci (VRE) in Swedish sewage sludge
Sahlström, L. M. O., Rehbinder, V., Albihn, A., Aspán, A., & Bengtsson, B. (2009) · Acta veterinaria Scandinavica · doi:10.1186/1751-0147-51-24 · Cited by 44
“Electrophoresis was performed using a CHEF DRII apparatus (BioRad Laboratories, Richmond Calif., USA).”
BackgroundInfluentialMavros, M. N., Tansarli, G. S., Vardakas, K. Z., Rafailidis, P. I., Karageorgopoulos, D. E., & Falagas, M. E. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.07.023 · Cited by 45
“20 06 –2 00 7, U SA 99 [9 3] p ts ; m ea n ag e 66 .”
BackgroundFarr, B. M. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.12.001 · Cited by 45
“The third article described 1 of the 2 vancomycin-resistant S aureus cases reported in the United States during 2002.(22) Pulsed field gel electrophoresis showed the patient’s vancomycin-resistant S aureus to be identical to the methicillin-resistant S aureus (MRSA) of the patient and her friend.”
BackgroundCurrent knowledge about and recommendations for ocular methicillin-resistant Staphylococcus aureus
Mah, F. S., Davidson, R., Holland, E. J., Hovanesian, J. A., John, T., Kanellopoulos, J. A., Shamie, N., Starr, C. E., Vroman, D. T., & Kim, T. (2014) · Journal of Cataract & Refractive Surgery · doi:10.1016/j.jcrs.2014.09.023 · Cited by 48
Key considerations in the treatment of complicated staphylococcal infections
Jones, R. N. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01923.x · Cited by 22
“In contrast, the first naturally occurring, definitively VRSA isolate was reported in the USA in June 2002 [36].”
BackgroundStaphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings
Spagnolo, A. M., Orlando, P., Panatto, D., Amicizia, D., Perdelli, F., & Cristina, M. L. (2015) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2014.55.4.454 · Cited by 56
“[29] Chang S, Sievert DM, Hageman JC, et al.”
BackgroundOlonitola, O. S., Fahrenfeld, N. L., & Pruden, A. J. (2015) · Poultry Science · doi:10.3382/ps/pev069 · Cited by 44
“Resistance to vancomycin is mediated by the vanA gene in Staphylococcus aureus (Chang et al., 2003) and it was detected in 3 Staphylococcus isolates in the present study.”
BackgroundParodi, S. M., Rhew, D. C., & Goetz, M. B. (2003) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2003.9.4.317 · Cited by 44
Zuo, G., Zhang, X.-J., Han, J. H., Li, Y., & Wang, G.-C. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0938-3 · Cited by 45
“aureus (VRSA) has also been reported [4].”
Molecular and clinical epidemiology of vancomycin-resistant Enterococcus faecalis
Oprea, S. F., Zaidi, N., Donabedian, S. M., Balasubramaniam, M., Hershberger, E., & Zervos, M. J. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh138 · Cited by 49
“Isolates were from blood (21), urine (39), wounds (10), intra-abdominal sources (6), catheter tip (4), respiratory secretions (1), joints (1) and stool (1).”
BackgroundSingh, V., Kumar, V., Kashyap, S., Singh, A. V., Kishore, V., Sitti, M., Saxena, P. S., & Srivastava, A. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00757 · Cited by 43
The Changing Face of Antibiotic Prescribing: The Mutant Selection Window
Epstein, B. J., Gums, J. G., & Drlica, K. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e041 · Cited by 50
Total Synthesis and Absolute Configuration Assignment of MRSA Active Garcinol and Isogarcinol
Socolsky, C., & Plietker, B. J. (2014) · Chemistry - A European Journal · doi:10.1002/chem.201406077 · Cited by 43
Development of Tyrocidine A analogues with improved antibacterial activity
Marques, M. A., Citron, D. M., & Wang, C. C. C. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.08.007 · Cited by 43
“(1): Isolated as a fine white powder (7.”
BackgroundRajan, B. M., & Каннабиран, К. (2014) · PubMed Central · Cited by 42
Rincón, S., Panesso, D., Díaz, L., Carvajal, L. P., Reyes, J., Munita, J. M., & Arias, C. A. (2014) · Biomédica · doi:10.7705/biomedica.v34i0.2210 · Cited by 55
“aureus resistente a la vancomicina (SARV) por la adquisición del grupo de genes vanA ‘donados’ por cepas de enterococos resistentes a la vancomicina (23,24).”
BackgroundWang, Y., Li, X., Jiang, L., Han, W., Xie, X., Jin, Y., He, X., & Wu, R. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02163 · Cited by 47
“VRSA emerged in 1997 due to acquisition of the vanA gene from vancomycin-resistant enterococci (Hiramatsu et al., 1997a; Chang et al., 2003).”
Background
Metadata
- Authors
- Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes, F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., Cardo, D., & Fridkin, S. K.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Michigan Department of Health and Human Services (US)
- Wayne State University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-03
- Volume
- 348
- Issue
- 14
- Pages
- 1342-1347
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068037991
- Semantic Scholar
- f0afb59f819a65ada63076a36807f63502c4437d
- Cited by
- 1,095
- References
- 18
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 24 · 2023: 28 · 2022: 24 · 2021: 35 · 2020: 29 · 2019: 39 · 2018: 28 · 2017: 29 · 2016: 28 · 2015: 55 · 2014: 54 · 2013: 51 · 2012: 65
- FWCI
- 54.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- vancomycin-resistant Staphylococcus aureus, vanA gene, vancomycin resistance, diabetes mellitus, peripheral vascular disease, foot ulcer, vancomycin-resistant Enterococcus faecalis, antibiotic resistance transfer, catheter-related infection
- MeSH terms
- Adult, Catheterization, Debridement, Female, Renal Dialysis, Humans, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Contact Tracing, Diabetic Foot, Vancomycin Resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.